← Insider buys

DGX

Quest Diagnostics Incorporated · Healthcare

Insiders sold $35.5M of Quest Diagnostics Incorporated in the last 12 months and bought none

$0Bought, 12 mo
$35.5MSold, 12 mo
$25.9BMarket cap

DGX over the last year

No insider buys filed in this year

DGX after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Congress

Members reported 19 trades in DGX since 2023.

Every filing

147 insider filings since 2016, newest first

DGXSell

J. E. Davis · CEO and President

$2.4M−7.6%Sep 3
DGXSell

Michael E Prevoznik · SVP and General Counsel

$5.5M−37.6%Aug 31
DGXSell

Mark E Delaney · SVP and Chief Commercial Officer

$376K−13.4%Jul 29
DGXSell

Karthik Kuppusamy · SVP, Clinical Solutions

$1.6M−37.6%Jun 8
DGXSell

J. E. Davis · CEO and President

$1.9M−7.0%Jun 2
DGXSell

Patrick Plewman · SVP for Diagnostic Services

$589K−16.0%Mar 6
DGXSell

Karthik Kuppusamy · SVP, Clinical Solutions

$538K−15.0%Mar 6
DGXSell

Catherine T. Doherty · EVP, Regional Businesses

$1.1M−7.0%Mar 6
DGXSell

Michael E Prevoznik · SVP and General Counsel

$800K−8.0%Mar 6
DGXSell

Patrick Plewman · SVP for Diagnostic Services

$85K−3.0%Mar 4
DGXSell

Catherine T. Doherty · EVP, Regional Businesses

$131K−1.0%Mar 4
DGXSell

Michael E Prevoznik · SVP and General Counsel

$109K−1.0%Mar 4
DGXSell

J. E. Davis · CEO and President

$2.1M−8.0%Mar 4
DGXSell

Patrick Plewman · SVP for Diagnostic Services

$196K−6.0%Feb 20
DGXSell

Michael E Prevoznik · SVP and General Counsel

$228K−2.0%Feb 20
DGXSell

Catherine T. Doherty · EVP, Regional Businesses

$294K−2.0%Feb 20
DGXSell

Catherine T. Doherty · EVP, Regional Businesses

$5.4M−26.0%Feb 17
DGXSell

Patrick Plewman · SVP for Diagnostic Services

$1.2M−27.0%Feb 12
DGXSell

Vicky B Gregg · Director

$240K−7.0%Nov 28
DGXSell

J. E. Davis · CEO and President

$10.6M−31.0%Nov 28
DGXSell

Michael J Deppe · SVP, Corp. Controller, CAO

$2.9M−34.0%Nov 7
DGXSell

Karthik Kuppusamy · SVP, Clinical Solutions

$279K−13.0%Oct 30
DGXSell

Michael E Prevoznik · SVP and General Counsel

$5.0M−42.0%Sep 3
DGXSell

Karthik Kuppusamy · SVP, Clinical Solutions

$305K−13.0%Aug 29
DGXSell

Mark E Delaney · SVP and Chief Commercial Officer

$60K−8.0%Jul 26
DGXSell

Karthik Kuppusamy · SVP, Clinical Solutions

$246K−10.0%May 1
DGXSell

Catherine T. Doherty · EVP, Regional Businesses

$853K−8.0%Mar 1
DGXSell

Michael E Prevoznik · SVP and General Counsel

$706K−11.0%Mar 1
DGXSell

Vicky B Gregg · Director

$317K−13.0%Feb 23
DGXSell

Michael E Prevoznik · SVP and General Counsel

$83K−1.0%Feb 23
DGXSell

Catherine T. Doherty · EVP, Regional Businesses

$104K−1.0%Feb 23
DGXSell

Michael E Prevoznik · SVP and General Counsel

$668K−10.0%Mar 8
DGXSell

Catherine T. Doherty · SVP, Regional Businesses

$746K−7.0%Mar 8
DGXSell

Catherine T. Doherty · SVP, Regional Businesses

$101K−1.0%Mar 6
DGXSell

Michael E Prevoznik · SVP and General Counsel

$82K−1.0%Mar 3
DGXSell

Michael E Prevoznik · SVP and General Counsel

$200K−3.0%Feb 27
DGXSell

Catherine T. Doherty · SVP, Regional Businesses

$239K−2.0%Feb 27
DGXSell

Timothy M Ring · Director

$309K−8.0%Dec 5
DGXSell

Catherine T. Doherty · SVP, Regional Businesses

$6.1M−36.0%Nov 29
DGXSell

Timothy M Ring · Director

$288K−8.0%Nov 2
DGXSell

Michael J Deppe · VP, Corp. Controller, CAO

$2.2M−32.0%Oct 27
DGXSell

Timothy M Ring · Director

$247K−8.0%Oct 4
DGXSell

Timothy M Ring · Director

$250K−8.0%Sep 6
DGXSell

Timothy M Ring · Director

$272K−8.0%Aug 2
DGXSell

Timothy M Ring · Director

$267K−8.0%Jul 5
DGXSell

Stephen H Rusckowski · Chair, CEO and President

$3.5M−7.0%May 26
DGXSell

Stephen H Rusckowski · Chair, CEO and President

$50.4M−52.0%May 25
DGXSell

Michael E Prevoznik · SVP and General Counsel

$7.1M−53.0%May 19
DGXSell

Michael E Prevoznik · SVP and General Counsel

$842K−12.0%Mar 9
DGXSell

Catherine T. Doherty · SVP, Group Exec. Clin. Fran.

$951K−9.0%Mar 9
About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.